Hisun Pharmaceutical: The company and Wangshi Biological intend to establish cooperation in the fields of small molecule innovative drug VV116 product processing, production, international registration, market development and other fields_Oriental Fortune Network

Every time we pass the AI ​​Express, an investor asks a question on the investor interactive platform: Hello, Secretary of the Board of Directors! In the history of the company, the company has made special raw materials. The asset situation determines that the company can only make some high value-added, distinctive and technical barriers. The EU has not lifted the ban in the short term, and it will definitely explore more opportunities in the domestic market. .May I ask whether the company’s raw material business is in line with the recent popularJunshi BiologyHave a matchmaking negotiation? If not, what is the company’s layout in the business direction of new crown APIs?

Hisun Pharmaceutical (600267.SH) stated on the investor interaction platform on May 27 that the company and Wangshi Bio will establish a strategic partnership in the fields of product processing, production, international registration, and market development of the small molecule innovative drug VV116. And on May 19, 2022, signed the “Strategic Cooperation Agreement” and “Entrusted Production Framework Agreement” on VV116 cooperation. For details, please pay attention to the relevant information disclosed by the company on May 20, 2022.announcement.Whether the company has negotiated and cooperated with other enterprises and the layout of APIs, etc.Company Announcementprevail.

(Article source: Daily Economic News)

Article source: Daily Economic News

Responsible editor: 436

Original title: Hisun Pharmaceutical: The company and Wangshi Biological intend to establish cooperation in the fields of small molecule innovative drug VV116 product processing, production, international registration, market development and other fields